Marinus Pharmaceuticals (NASDAQ:MRNS) Receives “Hold” Rating from Jefferies Financial Group

Jefferies Financial Group restated their hold rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report published on Friday, Benzinga reports. Jefferies Financial Group currently has a $0.50 price target on the biopharmaceutical company’s stock, down from their previous price target of $5.00.

Several other equities analysts have also commented on MRNS. StockNews.com raised Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, October 4th. LADENBURG THALM/SH SH lowered Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 14th. HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of Marinus Pharmaceuticals in a research report on Wednesday, August 14th. Oppenheimer upgraded Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target for the company in a report on Monday, September 23rd. Finally, EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. Eight equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $6.07.

Marinus Pharmaceuticals Trading Down 7.8 %

Shares of Marinus Pharmaceuticals stock opened at $0.37 on Friday. The firm has a market capitalization of $20.57 million, a P/E ratio of -0.14 and a beta of 1.14. The business has a fifty day simple moving average of $1.52 and a two-hundred day simple moving average of $1.46. Marinus Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.01). The firm had revenue of $8.06 million for the quarter, compared to analysts’ expectations of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. During the same period in the prior year, the business posted ($0.61) EPS. Analysts predict that Marinus Pharmaceuticals will post -1.93 earnings per share for the current year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Several large investors have recently bought and sold shares of MRNS. Point72 DIFC Ltd bought a new stake in Marinus Pharmaceuticals in the 2nd quarter worth about $28,000. SG Americas Securities LLC bought a new stake in Marinus Pharmaceuticals in the 2nd quarter worth about $34,000. AQR Capital Management LLC increased its holdings in Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 12,934 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Marinus Pharmaceuticals in the 2nd quarter worth about $64,000. Finally, Values First Advisors Inc. increased its holdings in Marinus Pharmaceuticals by 501.8% in the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 52,257 shares in the last quarter. 98.80% of the stock is currently owned by institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.